Back to Browse Journals » Therapeutics and Clinical Risk Management » Volume 1 » Issue 1

Differential associations between actual and expected GP practice prescribing rates for statins, ACE inhibitors, and beta-blockers: a cross-sectional study in England

Authors Paul R Ward, Peter R Noyce, Antony S St Leger

Published 15 April 2005 Volume 2005:1(1) Pages 61—68

Paul R Ward1, Peter R Noyce2, Antony S St Leger3

1School of Health and Related Research, University of Sheffield, England, UK; 2School of Pharmacy and Pharmaceutical Sciences, University of Manchester, England, UK; 3School of Epidemiology and Health Sciences, University of Manchester, England, UK

Aim: To explore the relationship between actual and expected general medical practitioner (GP) practice prescribing rates for statins, angiotensin converting enzyme (ACE) inhibitors, and beta-blockers.

Background: There is a growing body of literature highlighting inequities in GP practice prescribing rates for many drug therapies. The equity of prescribing is of central importance in the area of therapeutics since it explores the interface between those patients who should and those who actually do receive a drug therapy.

Setting: Four primary care trusts (PCTs 1–4) in the North West of England, including 132 GP practices.

Methods: Actual and expected prescribing rates for statins, beta-blockers, and ACE inhibitors were specifically developed for each GP practice.

Results: There were no statistically significant correlations between actual and expected prescribing rates in PCT2 and PCT3, although in PCT1 there were statistically significant correlations for statins (0.286, p < 0.05) and ACE inhibitors (0.381, p < 0.01). In PCT4, correlations were moderate to high for beta-blockers (0.693, p < 0.01), and moderate for statins (0.541, p < 0.05) and ACE inhibitors (0.585, p < 0.01). Scatterplots highlighted large variations between individual GP practices (both within and between PCTs) in terms of the relationship between actual and expected prescribing rates.

Conclusion: This paper highlights variability between PCTs and GP practices in terms of the relationship between actual and expected prescribing rates. The findings from this paper may further advance the suggestion of inequities in prescribing rates for coronary heart disease (CHD) drugs, and studies such as this may be repeated in different therapeutic areas, healthcare settings, and countries.

Keywords: prescribing rates, equity, coronary heart disease, statins, beta-blockers, ACE inhibitor

Download Article [PDF] 

Readers of this article also read:

Comparison of echinocandin antifungals

Gregory Eschenauer, Daryl D DePestel, Peggy L Carver

Therapeutics and Clinical Risk Management 2007, 3:71-97

Published Date: 15 March 2007

Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4

Shufeng Zhou, Eli Chan, Xiaotian Li, Min Huang

Therapeutics and Clinical Risk Management 2005, 1:3-13

Published Date: 15 April 2005

Should valproate be taken during pregnancy?

Mervyn J Eadie, Frank JE Vajda

Therapeutics and Clinical Risk Management 2005, 1:21-26

Published Date: 15 April 2005

Patient medication knowledge and adherence to asthma pharmacotherapy: a pilot study in rural Australia

Tabitha J Franks, Deborah L Burton, Maree D Simpson

Therapeutics and Clinical Risk Management 2005, 1:33-38

Published Date: 15 April 2005

Depression and drug utilization in an elderly population

Raffaele Antonelli Incalz, Andrea Corsonello, Claudio Pedone, Francesco Corica, Pierugo Carbonin

Therapeutics and Clinical Risk Management 2005, 1:55-60

Published Date: 15 April 2005

Principles in genetic risk assessment || FREE PAPER ||

Pedro Viana Baptista

Therapeutics and Clinical Risk Management 2005, 1:15-20

Published Date: 15 April 2005

Drug-related problems in hospitalized patients on polypharmacy: the influence of age and gender

Yvonne Koh, Fatimah Bte Moideen Kutty, Shu Chuen Li

Therapeutics and Clinical Risk Management 2005, 1:39-48

Published Date: 15 April 2005

Elective open abdominal aortic aneurysm repair: a seven-year experience

Stuart MacKenzie, judith R Swan, Cate D’Este,  Allan D Spigelman

Therapeutics and Clinical Risk Management 2005, 1:27-31

Published Date: 15 April 2005